Form 4 for JBIO Jade Biosciences, Inc.
Accepted 2024-05-03 00:00:00 ET · period of report 2024-05-01 · accession 0001415889-24-012234 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-05-03 | 2024-05-01 | JBIO | NOYES TIMOTHY P | CEO, Dir | M - OptEx | $2.14 | +10.0K | 10.0K | New | +$21.4K |
| DM | 2024-05-03 | 2024-05-01 | JBIO | NOYES TIMOTHY P | CEO, Dir | S - Sale+OE | $20.33 | -11.4K | 0 | -100% | -$230.9K |
| D | 2024-05-03 | 2024-05-01 | JBIO | NOYES TIMOTHY P | CEO, Dir | M - OptEx | $0.00 | -10.0K | 353.4K | -3% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-05-01 | M | A | 10,000 | $2.14 | 10,000 | D | — | — | |
| 2 | Common | Common Stock | 2024-05-01 | S | D | 9,035 | $20.34 | 965 | D | — | — | (F2) The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $19.855 to $20.85, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. |
| 3 | Common | Common Stock | 2024-05-01 | S | D | 965 | $20.87 | 0 | D | — | — | (F3) The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $20.855 to $20.89, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. |
| 4 | Common | Common Stock | 2024-05-01 | S | D | 1,357 | $19.91 | 0 | D | — | — | (F4) Includes 1,357 shares purchased under the Issuer's 2021 Employee Stock Purchase Plan on April 30, 2024 in a transaction that is exempt under Rule 16b-3(c) and 16b-3(d). |
| 5 | Derivative | Stock Option (Right to Buy) | 2024-05-01 | M | D | 10,000 | $0.00 | 353,381 | D | $2.14 · — to 2031-04-01 | 10,000 Common Stock | (F5) A total of 493,381 shares subject to an employee stock option were granted on April 2, 2021, with 25% vested on June 4, 2022, with the remainder vesting in 36 substantially equal monthly installments thereafter. |